Lund, Sweden, 12:00 pm CET, 31 January 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has signed an agreement with Skandinaviska Enskilda Banken (SEB) for a credit facility of up to SEK 60 million.
The credit line is an overdraft facility with collateral in floating charges and terms and conditions in line with previously communicated growth targets, so called covenants. The facility has a maturity of twelve plus twelve months and strengthens BONESUPPORT’s ability to pursue a continued growth strategy.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio–ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:00 pm CET on 31 January 2020.